The echinocandins are a new class of antifungal agents that target the fungal cell wall by inhibiting 1,3-β-d-glucan synthetase (5). Caspofungin and the recently approved echinocandins micafungin and anidulafungin have broad-spectrum fungicidal activity against Candida species and have been shown to be active for the treatment of invasive candidiasis (3, 5, 7, 11).. Of concern, however, is the paradoxical growth of some Candida albicans isolates in vitro (12, 15) and in vivo (4) observed at caspofungin concentrations that are high yet theoretically achievable in humans. This phenomenon has similarities to the paradoxical, or eagle, effect observed for other cell wall-active antimicrobial agents, such as penicillins. Although the molecular mechanisms responsible for the paradoxical effect of echinocandins remain largely unknown, it has been postulated that stress response pathways, such as the cell wall integrity and calcineurin pathways (14, 16), play a critical role. Hence, a compensatory ...
TY - JOUR. T1 - Development of candidemia on caspofungin therapy. T2 - A case report. AU - Cheung, C.. AU - Guo, Y.. AU - Gialanella, P.. AU - Feldmesser, M.. PY - 2006/12/1. Y1 - 2006/12/1. N2 - Caspofungin, an echinocandin, is approved for use in invasive candidiasis. Few cases of break-through candidal infections during caspofungin therapy have been reported and none have involved Candida parapsilosis. Here, we report a patient who developed multiple post-operative complications after pancreaticoduodenectomy for a pancreatic mass, including fungemia due to C. parapsilosis, while on caspofungin for treatment of Candida glabrata peritonitis. The fungemia resolved after a central venous catheter was removed and therapy was switched from caspofungin to amphotericin B lipid complex. Studies of C. parapsilosis susceptibility and the pharmacodynamics and drug interactions of caspofungin that may contribute to breakthrough fungemia are discussed.. AB - Caspofungin, an echinocandin, is approved for ...
Search Indian caspofungin acetate Manufacturers and Suppliers Details - Contact to caspofungin acetate Exporters in India, caspofungin acetate Wholesalers, caspofungin acetate Distributors and Traders from India.
Introduction. Invasive infections caused by Candida spp. in critically ill patients may significantly worsen their prognosis, so it is of great importance to establish an early detection and a suitable therapeutic strategy. The objective of this study was to define the differential role of echinocandins in treating certain critical patient profiles.Methodology. A scientific committee of 9 experts in infectious diseases, critical care, microbiology, and hospital pharmacy reviewed the existing evidence on the treatment of candidemia and invasive candidiasis in critically ill patients. After that, a questionnaire with 35 items was elaborated to be agreed by 26 specialists in the aforementioned disciplines using a modified Delphi method.Results. After two rounds of evaluation, a consensus was reached in terms of agreement in 66% of the items. Some of the consensuses achieved included: it is not necessary to adjust the dose of echinocandins during renal replacement therapy; the echinocandins are the ...
TY - JOUR. T1 - MSG-10. T2 - a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. AU - Mycoses Study Group AU - Spec, Andrej. AU - Pullman, John. AU - Thompson, George Richard. AU - Powderly, William G.. AU - Tobin, Ellis H.. AU - Vazquez, Jose. AU - Wring, Stephen A.. AU - Angulo, David. AU - Helou, Silvia. AU - Pappas, Peter G.. PY - 2019/10/1. Y1 - 2019/10/1. N2 - OBJECTIVES: To evaluate the safety and efficacy of two dosing regimens of oral ibrexafungerp (formerly SCY-078), a novel orally bioavailable β-glucan synthase inhibitor, in subjects with invasive candidiasis versus the standard of care (SOC) and to identify the dose to achieve target exposure (15.4 μM·h) in ,80% of the intended population. METHODS: In a multinational, open-label study, patients with documented invasive candidiasis were randomized to receive step-down therapy to one of three treatment arms: two dosing regimens of novel oral ...
TY - JOUR. T1 - Anidulafungin. T2 - A novel echinocandin. AU - Vazquez, Jose A.. AU - Sobel, Jack D.. PY - 2006/7/15. Y1 - 2006/7/15. N2 - Until recently, the treatment available for serious fungal infections was composed of amphotericin B and azoles, and each class demonstrated significant limitations. Echinocandins are a new class of drugs that have shown promising results in treating a variety of fungal infections. Of these, anidulafungin is a novel echinocandin that appears to have several advantages over existing antifungals. It is unique because it slowly degrades in humans, undergoing a process of biotransformation rather than being metabolized. It has potent in vitro activity against Aspergillus and Candida species, including those resistant to fluconazole or amphotericin B. Results of several clinical trials indicate that anidulafungin is effective in treating esophageal candidiasis, including azole-refractory disease. The results of a recent study comparing fluconazole versus ...
The need for the early diagnosis and treatment of fungal infections has been well documented (13, 16, 19). Caspofungin, an FDA-approved antifungal agent of the echinocandin family, has been shown to be effective in the treatment of a variety of fungal infections, including those caused by Candida species (1, 2). It is the first drug of its class to be approved for use by the FDA. It also has been shown to be effective in vitro against isolates with decreased susceptibility to amphotericin B or to the azole compounds (15, 20). Although there are case reports of caspofungin resistance among clinical isolates of Candida (9, 11, 12, 14), surveillance studies have not demonstrated the widespread emergence of caspofungin resistance among clinical isolates causing invasive candidiasis (17). The CLSI has developed and approved standardized testing methodologies under which antifungal agents should be tested. These methodologies include both broth microdilution (6, 7) and disk diffusion techniques (5, ...
FIG. 1. Detection of the T1933C mutation in both the homozygous and heterozygous states. The graph summarizes results of four separate PCRs with individual allele-specific molecular beacons and DNA targets. Squares, FKS1(T1933C) beacon plus DNA of the FKS1 allele with a homozygous T1933C mutation; circles, FKS1(WT) beacon plus DNA of the FKS1 allele with a homozygous T1933C mutation; asterisks, FKS1(T1933C) beacon plus DNA of the FKS1 allele with a heterozygous T1933C mutation; diamonds, FKS1(WT) beacon plus DNA of the FKS1 allele with a heterozygous T1933C mutation. ...
Aspergillosis remains to be a life-threatening complication in immunocompromised patients. However, Aspergillus infection can be observed in non-immunocompromised individuals in rare cases. We report a case of liver aspergilloma in a chronic aplastic anemia patient under relatively intact immune status. Therapeutic strategy for this rare condition was extensively discussed and caspofungin acetate single agent first-line therapy was applied after careful consideration. Encouraging clinical and radiologic improvements were achieved in response to the antifungal salvage. Our long-term follow-up study also revealed a favorable prognosis. Based on this experience, we suggest caspofungin acetate as first-line therapy for treatment plans of liver aspergilloma.
Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against many Candida, as well as some Aspergillus. Like other echinocandins, anidulafungin is not active against Cryptococcus neoformans, Trichosporon, Fusarium, or zygomycetes ...
Echinocandins, such as anidulafungin are first line treatment for candidemia or invasive candidiasis in critically ill patients. There is conflicting data on the pharmacokinetic properties of anidulafungin in ICU patients. Adult ICU patients (from 3 hospitals) receiving anidulafungin for suspected or proven fungal infections were included. Patient were considered evaluable ... read more when a pharmacokinetic curve on day 3 could be completed. 23 out of 36 patients (7 female, 16 male) were evaluable. Median (range) age and bodyweight were 66 (28-88) yr and 76 (50-115) kg. Pharmacokinetic sampling on day 3 (n=23) resulted in a median anidulafungin AUC0-24h of 72.1 (IQR 61.3-94.0) mg*h*L(-1), a median C24 of 2.2 (IQR 1.9-2.9) mg/L, a median Cmax of 5.3 (IQR 4.1-6.0) mg/L, a median Vd of 46.0 (IQR 32.2-60.2) L and a median CL of 1.4 (IQR 1.1-1.6) L*h-1. Pharmacokinetic sampling on day 7 (n=13) resulted in a median AUC0-24h of 82.7 (IQR 73.0 - 129.5) mg*h*L(-1), a median Cmin of 2.8 (IQR 2.2 - 4.2) ...
Learn Echinocandins - Antifungals - Pharmacology - Picmonic for Medicine faster and easier with Picmonics unforgettable images and stories! Picmonic is research proven to increase your memory retention and test scores. Start learning today for free!
Caspofungin acetate was found in Pediatrics Central. Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents.
As technical issues in the laboratory have made formal proof of the assertion that this enzyme is actual target of these compounds, it is most correct to speak of them at present as being glucan synthesis inhibitors rather than glucan synthase inhibitors. There are three such agents at present, with all three belonging to the chemical family also known as the echinocandins: caspofungin, micafungin, and anidulafungin. As would be predicted from their mechanism of action, these agents appear to be well-tolerated and have relatively fewer toxicities than polyene or azole-class antifungals. Indeed, maximum tolerated dosages were not reached, in human volunteers, for these agents in phase II clinical trials.. ...
A cyclic lipopeptide echinocandin derivative with antifungal activity. Anidulafungin inhibits 1,3 beta-D-glucan synthase, an enzyme involved in fungal cell wall synthesis, resulting in cell lysis and death. This agent is active against Candida species and Aspergillus.. ...
Sigma-Aldrich offers abstracts and full-text articles by [Christian Koch, Florian Uhle, Matthias Wolff, Christoph Arens, Astrid Schulte, Ling Li, Bernd Niemann, Michael Henrich, Susanne Rohrbach, Markus A Weigand, Christoph Lichtenstern].
ERAXIS (Anidulafungin) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
Eraxis with NDC 0049-0114 is a a human prescription drug product labeled by Roerig. The generic name of Eraxis is anidulafungin.
TY - JOUR. T1 - In vitro activity of the New Echinocandin Antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. AU - Barchiesi, F.. AU - Schimizzi, A. M.. AU - Fothergill, A. W.. AU - Scalise, G.. AU - Rinaldi, M. G.. PY - 1999/11/22. Y1 - 1999/11/22. N2 - A broth macrodilution method, performed as recommended by the National Committee for Clinical Laboratory Standards, was used for comparative testing of the new echinocandin antifungal agent MK-0991 and fluconazole against 50 yeast isolates belonging to 12 species of Candida. MK-0991 was shown to be highly effective against both fluconazole-susceptible and -resistant Candida spp., yielding minimum inhibitory concentrations ranging from ≤ 0.19 to 0.78 μg/ml. Fungicidal activity was exerted at ≤ 1.5 μg/ml for 73% of the isolates tested. This study suggests that MK-0991 has significant potential for clinical development.. AB - A broth macrodilution method, performed as recommended by the National Committee ...
PRIMARY OBJECTIVES:. I. To determine if caspofungin (caspofungin acetate) is associated with a lower incidence of proven/probable invasive fungal infections (IFI) during the first 42 days following allogeneic hematopoietic cell transplantation (HCT) at high-risk for IFI compared with azole (fluconazole or voriconazole) prophylaxis.. SECONDARY OBJECTIVES:. I. To determine if caspofungin is associated with a lower incidence of proven/probable IFI during the first 100 days following high-risk allogeneic HCT compared with azole (fluconazole or voriconazole) prophylaxis. (Exploratory) II. To determine if caspofungin is associated with a lower incidence of proven/probable IFI during the first 42 and 100 days following high-risk allogeneic HCT compared with fluconazole prophylaxis. (Exploratory) III. To determine if caspofungin is associated with a lower incidence of proven/probable IFI during the first 42 and 100 days following high-risk allogeneic HCT compared with voriconazole prophylaxis. ...
TY - JOUR. T1 - Breakthrough fungemia caused by Yarrowia lipolytica in a patient with gastric adenocarcinoma during echinocandin therapy. AU - Chi, Hsin Yu. AU - Su, Ying Shih. AU - Chen, Fu Lun. AU - Lee, Wen Sen. AU - Wang, Cheng Hui. PY - 2021/1. Y1 - 2021/1. UR - http://www.scopus.com/inward/record.url?scp=85099121397&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85099121397&partnerID=8YFLogxK. U2 - 10.1016/j.jinf.2020.12.008. DO - 10.1016/j.jinf.2020.12.008. M3 - Letter. C2 - 33338504. AN - SCOPUS:85099121397. VL - 82. SP - e52-e53. JO - Journal of Infection. JF - Journal of Infection. SN - 0163-4453. IS - 1. ER - ...
In contrast, C. parapsilosis, our most common breakthrough Candida spp., has not been associated with characteristic hot-spot mutations. Instead, a naturally occurring polymorphism in the FKS gene is thought to confer higher echinocandin MICs. Among 759 C. parapsilosis isolates recovered in global surveillance, the MIC90 of micafungin was 2 μg/ml, although no organism had an MIC of ,2 μg/ml (42). The amino acid substitution of proline for alanine (P660A) encoded in the FKS1 hot-spot region of C. parapsilosis appears to be responsible for the intrinsically higher MICs (12). In our C. parapsilosis breakthrough isolates, none had characteristic hot-spot mutations but all contained the naturally occurring P660A substitution and mixed echinocandin MICs. Eighty-three percent (5/6) of our C. parapsilosis isolates had nonsusceptible micafungin MICs (range, 4 to 8 μg/ml), a finding which clearly differs from the global surveillance data (42). These six isolates all had caspofungin MICs of 0.5 to 1 ...
Anidulafungin inhibits glucan synthase, an enzyme important in the formation of β (1,3)-D-glucan, a major fungal cell wall component. Glucan synthase is not present in mammalian cells and therefore is an attractive target for antifungal activity.. Anidulafungin or Eraxis (Ecalta in Europe) is an antifungal drug. It was previously known as LY303366. There is preliminary evidence it has a similar safety profile to caspofungin. It has proven efficacy against oesophageal candidiasis, but its main use will probably be in invasive Candida infection; it will probably also have application in treating invasive Aspergillus infection. It is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of (1→3)β-D-glucan synthase, which is an important component of the fungal cell wall.. Appearence: White Powder. Store: 2-8°C. Free Shipping within the Continental USA. ...
Pfizer Limited today welcomes the Scottish Medicines Consortium (SMC) advice, which recommends Ecalta (anidulafungin), a new antifungal medicine for the treatment of invasive candidiasis in NHS Scotland.1 Following a re-submission, the SMCs decision to recommend anidulafungin comes after results of the cost-minimisation analysis which indicated that anidulafungin would be preferred to both caspofungin and liposomal amphotericin B, with savings of 772 and 2,375 respectively, as a
Candidaemia and other forms of invasive candidiasis (C/IC) in the intensive care unit are challenging conditions that are associated with high rates of mortality. New guidelines from the European Society for Clinical Microbiology and Infectious Diseases strongly recommend echinocandins for the first-line treatment of C/IC. Here, a cost-effectiveness model was developed from the United Kingdom perspective to examine the costs and outcomes of antifungal treatment for C/IC based on the European Society for Clinical Microbiology and Infectious Diseases guidelines. Costs and treatment outcomes with the echinocandin anidulafungin were compared with those for caspofungin, micafungin and fluconazole. The model included non-neutropenic patients aged ≥16 years with confirmed C/IC who were receiving intravenous first-line treatment. Patients were categorised as either a clinical success or failure (patients with persistent/breakthrough infection); successfully treated patients switched to oral therapy, while
RATIONALE: Caspofungin acetate, fluconazole, and voriconazole may be effective in preventing fungal infections in patients following donor stem cell tra
Background: Over the past 5 decades, therapeutic options for invasive fungal infections have remained limited and sub-optimal. Recently, novel antifungal agents like caspofungin and voriconazole have been approved for use. These antifungals offer an advancement in antifungal therapy; however, clinical experience with these agents is limited. We therefore sought to examine how these agents are being used and their impact on patient outcomes at an urban medical center. Methods: The charts of the first 15 patients receiving voriconazole and 15 consecutive patients receiving caspofungin were retrospectively identified and reviewed. Data extraction included patient demographics, past medical history, current admission diagnosis, laboratory values, radiology results, microbiology, and antifungal use. Follow up care in outpatient clinics were reviewed for patient outcome and radiological improvements, when available. Results: 11 patients received antifungal treatment with caspofungin, 3 with ...
SCY-078 is an antifungal agent in clinical development for the treatment of fungal infections caused by Candida and Aspergillus species. SCY-078 is a triterpenoid, semi-synthetic derivative of the natural product enfumafungin - a structurally distinct and novel class of glucan synthase inhibitor. SCY-078 combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having IV and oral formulations. By belonging to a chemical class distinct from other antifungals, SCY-078 has shown in vitro and in vivo activity against multi-drug resistant pathogens, including azole- and echinocandin-resistant strains. The U.S. Food and Drug Administration granted Fast Track, Qualified Infectious Disease Product and Orphan Drug Designations for the formulations of SCY-078 for the indications of invasive candidiasis (including candidemia) and invasive aspergillosis.. About ...
Whilst micafungin (Mycamine®) has much to offer, little is known about its pharmacokinetic profile in ICU patients with specific co-morbidities such as obesity, hypoalbumenia, and severe liverfunction disturbances. Also, ICU patients are known to experience changes in pharmacokinetics (PK) due to changes in hemodynamics, extracorporeal elimination techniques, interacting comedication, etc. Based on criteria outlined below, micafungin may prove to be the drug of choice in this cohort of patients. Therefore it seems prudent to conduct a trial in a cohort of patients who receive micafungin but with co-variates that may be of influence to the pharmacokinetic profile. To build a valid pharmacokinetic model, all patients on micafungin will be included in the analysis and used for model building. Co-variates that will be explored are at least: obesitas, liverfunction, albumin, creatinin-clearance. Simulations will be performed to determine if adequate exposure is reached under different ...
Anidulafungin is an antifungal medication that fights infections caused by fungus. Anidulafungin treats candida (yeast) infections in the blood, or in the stomach or esophagus. Anidulafungin may also be used for purposes not listed in this medication guide.
Laboratory abnormalities in liver function tests have been seen in healthy volunteers and patients treated with caspofungin acetate. In some patients with serious underlying conditions who were receiving multiple concomitant medications along with caspofungin acetate, clinical hepatic abnormalities have also occurred. Isolated cases of significant hepatic dysfunction, hepatitis, or worsening hepatic failure have been reported in patients; a causal relationship to caspofungin acetate has not been established ...
Fungal infections pose a significant public health burden with high morbidity and mortality. CD101 is a novel echinocandin under development for the treatment and prevention of systemic Candida infections. Preclinical studies were conducted to evaluate the metabolic stability, plasma protein binding, pharmacokinetics, toxicity, and efficacy of CD101 at various dose levels. CD101 was stable to biotransformation in rat/monkey/human liver microsomes and rat/monkey/dog/human hepatocytes. In vitro studies suggest minimal interaction with recombinant cytochrome P450 enzymes (IC50 values ,10 μM). Similar to anidulafungin, CD101 bound avidly (,98%) to human/mouse/rat/primate plasma proteins. In a 2-week, repeat-dose comparison study, CD101 was well tolerated in rats (no effects on body weight, hematology, coagulation, or urinalysis). By contrast, administration of anidulafungin (at comparable exposure levels) resulted in reduced body weight; decreases in red blood cell, hemoglobin, hematocrit, mean ...
Summary: When either ERC or ARAF are suspected or proven, amphotericin products remain the cornerstone of initial therapy. For ERC, azoles are de-escalation options for susceptible isolates in stable patients to avoid amphotericin toxicities. Although combination echinocandin with high-dose salvage posaconazole or isavuconazole may be attempted in ARAF, it requires careful consideration following patient stabilization. Future research defining optimal therapies and early identification of ERC and ARAF is of extreme importance ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Background: Azoles and echinocandins are commonly used for treatment of invasive fungal infections. Resistance by Candida glabrata to echinocandins is emerging. Availability of antifungal susceptibility testing of bloodstream isolates (especially C. glabrata) is necessary for appropriate therapy. The aim of this study was to determine antifungal susceptibilities for C. glabrata and compare results from two testing methods. Methods: A total of 429 Candida blood culture isolates were collected from unique New Orleans patients during 2009-2015. Of these, 151 (35%) were C. glabrata (146 viable for testing). Caspofungin and fluconazole MICs were determined by two FDA-approved antifungal susceptibility testing methods, the Vitek® 2 system and the Etest® method. Vitek MICs were finalized in an average time of 13h; Etest MICs were read at 24h. Results: C. glabrata Vitek 2 and Etest determined caspofungin resistance ranged from 6% to 7%, respectively; fluconazole resistance, 12% to 23%, respectively. ...
Caspofungin is a member of the echinocandin class of antifungal agents that inhibit the synthesis of β 1,3 glucan thus disrupting fungal cell wall structure and function. Exposure of the Aspergillus fumigatus cultures to caspofungin (0.01, 0.1 or 1.0 μ g/ml) resulted in a reduction in cell growth, but the production of the epipolythiodioxopiperazine toxin, gliotoxin, was comparable, or greater, in cultures exposed to caspofungin than untreated controls. Exposure of A. fumigatus hyphae to 1.0 μ g/ml caspofungin for 4 h resulted in the release of amino acids ( P 0.01), protein ( P 0.002) and gliotoxin ( P 0.02). Cultures of A. fumigatus incubated in the presence of caspofungin for 4 or 24 h demonstrated enhanced gliotoxin release ( P 0.04 and 0.03, respectively) and biosynthesis ( P 0.04 and 0.03, respectively) compared to that by control cultures. The results presented here indicate that exposure of A. fumigatus to caspofungin results in increased cell permeability and an increase in the ...
Objectives: We investigated the effects of fluconazole and micafungin for the therapy of deep-seated candidiasis in a cyclophosphamide-induced immunosuppressed mouse model.. Methods: We used the experimental model of intraperitoneal fungal abscess caused by Candida albicans, as described previously.. Results and conclusions: Micafungin efficacy was equal to that of fluconazole in one-tenth dosage even in peritonitis. We also assessed the short-term (24 h) and long-term (8 days) therapeutic effects after the end of therapy. Although the therapeutic effect of fluconazole was similar to that of micafungin at 24 h after the end of therapy, the effect of micafungin was superior to that of fluconazole at 8 days after the end of therapy.. ...
Aspergillus fumigatus is an opportunistic fungal pathogen that causes invasive aspergillosis (IA), a life-threatening disease in immunocompromised humans. The echinocandin caspofungin, adopted as a second-line therapy in combating IA, is a β-1,3-glucan synthase inhibitor, which, when used in high concentrations, reverts the anticipated A. fumigatus growth inhibition, a phenomenon called the caspofungin paradoxical effect (CPE). The CPE has been widely associated with increased chitin content in the cell wall due to a compensatory upregulation of chitin synthase-encoding genes. Here, we demonstrate that the CPE is dependent on the cell wall integrity (CWI) mitogen-activated protein kinase MpkAMPK1 and its associated transcription factor (TF) RlmARLM1, which regulate chitin synthase gene expression in response to different concentrations of caspofungin. Furthermore, the calcium- and calcineurin-dependent TF CrzA binds to and regulates the expression of specific chitin synthase genes during the ...
Micafungin is an antifungal medication that fights infections caused by fungus. Micafungin is used to treat infections caused by the Candida fungus. Micafungin is also used to prevent Candida fungal infections in stem cell transplant patients. Micafungin is for use in adults and children who are at least 4 months old...
Sixty-nine patients between the ages of 18 and 80 with invasive aspergillosis were enrolled in an open-label, noncomparative study to evaluate the safety, tolerability, and efficacy of caspofungin. Enrolled patients had previously been refractory to or intolerant of other antifungal therapy (ies). Refractory patients were classified as those who had disease progression or failed to improve despite therapy for at least 7 days with amphotericin B, lipid formulations of amphotericin B, itraconazole, or an investigational azole with reported activity against Aspergillus. Intolerance to previous therapy was defined as a doubling of creatinine (or creatinine ≥2.5 mg/dL while on therapy), other acute reactions, or infusion-related toxicity. To be included in the study, patients with pulmonary disease must have had definite (positive tissue histopathology or positive culture from tissue obtained by an invasive procedure) or probable (positive radiographic or computed tomography evidence with ...
In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole Resistance: Caspofungin inhibits
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the articles Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the articles Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless ...
Viscoli, C. Recent Advances in the Management of Invasive Candidiasis. Drugs 69, 1-3 (2009). https://doi.org/10.2165/11315490-000000000-00000. Download ...
Conditions: Leukemia,; Allogeneic Stem Cell TransplantationIntervention: Drug: Caspofugin based combination therapySponsor: Shanghai Jiao Tong University School of MedicineRecruiting - verified November 2014...
Micafungin Acid Sodium Salt ;. Micafungin Sodium ;. FK463 (Sodium Salt) ;. CAS # 208538-73-2 ;. C56H70N9NaO23S ;. Exact Mass: 1291.4203 ;. ...
There is an urgent need for the development of new antifungal agents. A facile in vivo model that evaluates libraries of chemical compounds could solve some of the main obstacles in current antifungal discovery. We show ...
Erfaring savnes vedr. mindre børn. Forsigtighed tilrådes ved behandling af denne aldersgruppe. Begrænsede data tyder på, at caspofungin 25 mg/m2 dgl. til nyfødte og spædbørn (under 3 mdr.) og 50 mg/m2 dgl. til små børn (3-11 mdr.) kan overvejes ...
Your trusted lab partner for Fungitell® ß-D-Glucan Assay testing, Viracor Eurofins delivers your results faster, when it matters most.
Transcriptional regulation of chitin synthases by calcineurin controls paradoxical growth of Aspergillus fumigatus in response to caspofungin.
Susceptibility studies. In vitro susceptibility testing was performed using broth microdilution for filamentous fungi according to the CLSI document M38-A2.5 The MIC and MEC (minimal effective concentration) values were read at 48 and 72h. Due to the lack of clinical breakpoints for Thermoascus species, the following suggested cut off breakpoints were used: sensible (S), ≤1μg/ml; intermediate (I), 2μg/ml; and resistant (R), ≥4μg/ml.5 Pure active powders of known potency of amphotericin B (AMB) (USP, Rockville, MD), voriconazole (VRC) (Sigma-Aldrich), itraconazole (ITC) (Janssen Pharmaceutica, Beerse, Belgium), caspofungin (CSF) (Merk & Co., Inc., Rahway, USA), micafungin (MCF) (Astellas Pharma), and anidulafungin (ANF) (Pfizer) were tested. All tests were performed in duplicates. Paecilomyces variotii ATCC MYA 3630 was included as quality control.. Results indicated the good activity of the antifungals tested. Amphotericin B and azoles showed MIC values of 0.5 and 0.25μg/ml, ...
By Richard R. Watkins, MD, MS, FACP, FIDSA Professor of Internal Medicine, Northeast Ohio Medical University; Division of Infectious Diseases, Cleveland Clinic Akron General, Akron, OH Dr. Watkins reports no financial relationships relevant to this field of study. SYNOPSIS: In a large, randomized, double-blind, multicenter clinical trial, researchers found that isavuconazole did not meet the primary endpoint of noninferiority compared to caspofungin for candidemia and invasive candidiasis. SOURCE: Kullberg BJ, Viscoli C, Pappas PG, et al. Isavuconazole versus caspofungin in the treatment of candidemia and . . .
Results The number of antifungals purchased annually by the Haematology department decreased by 20.9%, compared with the overall decrease in the hospital of 22.04%. An increase in the use of echinocandins was noted, the number of DDDs prescribed increasing by 2.88%, Caspofungin being the most used (73.5%). The total DDDs of azoles decreased by 5.93%, oral voriconazole being the drug used less (-33.19%), while an increase in the use of posaconazole was observed (80.18%). The polyene antifungals experienced a higher reduction in use, the DDDs used dropping by 55.49%. The financial repercussions of this reduced use in the Haematology department represented a decrease in the amount of this pharmacological group of 102,200.68 €, contributing 31.36% of the savings achieved by this department in the hospitals total drugs bill.. ...
Anidulafungin. In: Ciccone CD. Ciccone C.D. Ed. Charles D. Ciccone.eds. Daviss Drug Guide for Rehabilitation Professionals New York, NY: McGraw-Hill; . http://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139001871. Accessed January 18, 2018 ...
SummaryInvasive fungal infections are a major cause of morbidity and mortality in immunocompromised children and premature neonates. The new class of echinocandin lipopeptides offers alternative options for treatment and prevention through a distinct mechanism of action, broad spectrum antifungal ac
The prevention and treatment of invasive fungal infections is being improved by the relatively recent introduction of new antifungal agents. While some of these agents offer better efficacy, others are proving their value more in improved tolerability, said John R. 1
Drug Store News breaks down the changes in consumer desires that retailers need to meet; names Dennis Wiesner the DSN 2017 Pharmacy Innovator of the Year; assesses the retail pharmacy opportunity for wearables; looks at how virtual makeovers are disrupting beauty; examines the bottled water category and much more! Read more.... ...
Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage, we no longer display the RxImage pill images associated with drug labels. We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels. ...
NOW® Beta-1,3/1,6-D-Glucan (beta-glukan)je bioaktivni polisaharid, izoliran iz celične stene pivskega kvasa (Saccharomyces cerevisiae). Znanstvene študije ...
FR 901379 is an impurity of Micafungin, a lipopeptide compound that acts as an antifungal agent with activity against Aspergillus and Candida species.